deferiprone has been researched along with Proteinuria in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 7.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "Deferasirox is an oral chelator." | 5.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 3.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "Deferasirox is an oral chelator." | 1.46 | Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. ( Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Totadri, S | 1 |
| Bansal, D | 1 |
| Bhatia, P | 1 |
| Attri, SV | 1 |
| Trehan, A | 1 |
| Marwaha, RK | 1 |
| Karimi, M | 1 |
| Avazpour, A | 1 |
| Haghpanah, S | 1 |
| Toosi, F | 1 |
| Badie, A | 1 |
| Economou, M | 1 |
| Printza, N | 1 |
| Teli, A | 1 |
| Tzimouli, V | 1 |
| Tsatra, I | 1 |
| Papachristou, F | 1 |
| Athanassiou-Metaxa, M | 1 |
| Rajapurkar, MM | 1 |
| Hegde, U | 1 |
| Bhattacharya, A | 1 |
| Alam, MG | 1 |
| Shah, SV | 1 |
1 trial available for deferiprone and Proteinuria
| Article | Year |
|---|---|
Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Diabetic Nephropathies; Drug Therapy, Combi | 2013 |
3 other studies available for deferiprone and Proteinuria
| Article | Year |
|---|---|
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I | 2015 |
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; De | 2017 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; | 2010 |